97 related articles for article (PubMed ID: 11471485)
1. Short-term tumor cell lines from breast cancer for use as autologous tumor cell vaccines in the treatment of breast cancer.
Dillman RO; Beutel LD; De Leon C; Nayak SK
Cancer Biother Radiopharm; 2001 Jun; 16(3):205-11. PubMed ID: 11471485
[TBL] [Abstract][Full Text] [Related]
2. Short-term tumor cell lines from renal cell carcinoma for use as autologous tumor cell vaccines in the treatment of kidney cancer.
Dillman RO; Beutel LD; Cornforth AN; Nayak SK
Cancer Biother Radiopharm; 2000 Apr; 15(2):161-8. PubMed ID: 10803321
[TBL] [Abstract][Full Text] [Related]
3. Treatment of kidney cancer with autologous tumor cell vaccines of short-term cell lines derived from renal cell carcinoma.
Dillman RO; Barth NM; VanderMolen LA; Garfield DH; De Leon C; O'Connor AA; Mahdavi K; Nayak SK
Cancer Biother Radiopharm; 2001 Feb; 16(1):47-54. PubMed ID: 11279797
[TBL] [Abstract][Full Text] [Related]
4. The feasibility of using short-term cultures of ovarian cancer cells for use as autologous tumor cell vaccines as adjuvant treatment of advanced ovarian cancer.
Dillman RO; Nayak SK; Brown JV; Mahdavi K; Beutel LD
Cancer Biother Radiopharm; 1999 Dec; 14(6):443-9. PubMed ID: 10850331
[TBL] [Abstract][Full Text] [Related]
5. Irradiated cells from autologous tumor cell lines as patient-specific vaccine therapy in 125 patients with metastatic cancer: induction of delayed-type hypersensitivity to autologous tumor is associated with improved survival.
Dillman RO; Beutel LD; Barth NM; de Leon C; O'Connor AA; DePriest C; Nayak SK
Cancer Biother Radiopharm; 2002 Feb; 17(1):51-66. PubMed ID: 11915174
[TBL] [Abstract][Full Text] [Related]
6. [Clinicopathological features and prognostic factors of breast cancer patients with inguinal lymph node metastases: a report of 17 cases].
Li Q; Xu BH; Zhang P; Li Q; Yuan P; Wang JY; Luo Y; Ma F; Fan Y; Li Q
Zhonghua Zhong Liu Za Zhi; 2013 Mar; 35(3):207-11. PubMed ID: 23880002
[TBL] [Abstract][Full Text] [Related]
7. Relationship of clinical and pathologic response to neoadjuvant chemotherapy and outcome of locally advanced breast cancer.
Gajdos C; Tartter PI; Estabrook A; Gistrak MA; Jaffer S; Bleiweiss IJ
J Surg Oncol; 2002 May; 80(1):4-11. PubMed ID: 11967899
[TBL] [Abstract][Full Text] [Related]
8. Primary and secondary distant metastatic breast cancer: two sides of the same coin.
Güth U; Magaton I; Huang DJ; Fisher R; Schötzau A; Vetter M
Breast; 2014 Feb; 23(1):26-32. PubMed ID: 24215983
[TBL] [Abstract][Full Text] [Related]
9. Comparison of immunity in mice cured of primary/metastatic growth of EMT6 or 4THM breast cancer by chemotherapy or immunotherapy.
Gorczynski RM; Chen Z; Erin N; Khatri I; Podnos A
PLoS One; 2014; 9(11):e113597. PubMed ID: 25409195
[TBL] [Abstract][Full Text] [Related]
10. Altered expression and activation of the nerve growth factor receptors TrkA and p75 provide the first evidence of tumor progression to effusion in breast carcinoma.
Davidson B; Reich R; Lazarovici P; Ann Flørenes V; Nielsen S; Nesland JM
Breast Cancer Res Treat; 2004 Jan; 83(2):119-28. PubMed ID: 14997042
[TBL] [Abstract][Full Text] [Related]
11. Pathologic tumor response in the breast following neoadjuvant chemotherapy predicts axillary lymph node status.
Kuerer HM; Newman LA; Buzdar AU; Dhingra K; Hunt KK; Buchholz TA; Binkley SM; Strom EA; Ames FC; Ross MI; Feig BW; McNeese MD; Hortobagyi GN; Singletary SE
Cancer J Sci Am; 1998; 4(4):230-6. PubMed ID: 9689981
[TBL] [Abstract][Full Text] [Related]
12. Phase I/II trial of autologous tumor cell line-derived vaccines for recurrent or metastatic sarcomas.
Dillman R; Barth N; Selvan S; Beutel L; de Leon C; DePriest C; Peterson C; Nayak S
Cancer Biother Radiopharm; 2004 Oct; 19(5):581-8. PubMed ID: 15650450
[TBL] [Abstract][Full Text] [Related]
13. Patients with recurrent breast cancer: does the primary axillary lymph node status predict more aggressive tumor progression?
Rack B; Janni W; Gerber B; Strobl B; Schindlbeck C; Klanner E; Rammel G; Sommer H; Dimpfl T; Friese K
Breast Cancer Res Treat; 2003 Nov; 82(2):83-92. PubMed ID: 14692652
[TBL] [Abstract][Full Text] [Related]
14. Occult metastases in the axillary lymph nodes of patients with breast cancer node negative by clinical and histologic examination and conventional histology.
Chen ZL; Wen DR; Coulson WF; Giuliano AE; Cochran AJ
Dis Markers; 1991; 9(5):239-48. PubMed ID: 1724633
[TBL] [Abstract][Full Text] [Related]
15. Sentinel node biopsy and cytokeratin staining for the accurate staging of 478 breast cancer patients.
Pendas S; Dauway E; Cox CE; Giuliano R; Ku NN; Schreiber RH; Reintgen DS
Am Surg; 1999 Jun; 65(6):500-5; discussion 505-6. PubMed ID: 10366202
[TBL] [Abstract][Full Text] [Related]
16. [Evaluation of modalities for recurrent breast cancer patients].
Tohnosu N; Onoda S; Okuyama K; Koide Y; Awano T; Kinoshita H; Matsubara H; Sano T; Nakaichi H; Isono K
Nihon Gan Chiryo Gakkai Shi; 1990 Dec; 25(12):2744-51. PubMed ID: 2074383
[TBL] [Abstract][Full Text] [Related]
17. Erratum to: Axillary recurrence rate following negative sentinel node biopsy for invasive breast cancer: long-term follow-up.
Kiluk JV; Ly QP; Santillan AA; Meade T; Ramos D; Reintgen DS; Dessureault S; Davis M; Shamehdi C; Cox CE
Ann Surg Oncol; 2010 Feb; 17(2):552-7. PubMed ID: 19957043
[TBL] [Abstract][Full Text] [Related]
18. [Diagnosis and surgical treatment of metastatic lung tumors].
Yamamoto Y; Hirata T; Fukuse T; Yokomise H; Ike O; Mizuno H; Wada H; Hitomi S; Nakamura T; Shimizu Y
Gan To Kagaku Ryoho; 1996 Sep; 23(10):1248-54. PubMed ID: 8831735
[TBL] [Abstract][Full Text] [Related]
19. Risk factors for regional nodal relapse in breast cancer patients with one to three positive axillary nodes.
Yates L; Kirby A; Crichton S; Gillett C; Cane P; Fentiman I; Sawyer E
Int J Radiat Oncol Biol Phys; 2012 Apr; 82(5):2093-103. PubMed ID: 21530101
[TBL] [Abstract][Full Text] [Related]
20. Presence of breast cancer antigens in uninvolved axillary lymph nodes.
Hendler FJ; House D
Cancer Res; 1985 Jul; 45(7):3364-73. PubMed ID: 4005859
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
